ViaOne Epicardial Access System

K243928 · Cardiovia , Ltd. · DYB · Mar 20, 2025 · Cardiovascular

Device Facts

• Record ID: K243928
• Device Name: ViaOne Epicardial Access System
• Applicant: Cardiovia , Ltd.
• Product Code: DYB · Cardiovascular
• Decision Date: Mar 20, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.1340
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The ViaOne Epicardial Access System is intended to access the epicardial surface of the heart via a subxiphoid approach to deliver diagnostic and therapeutic interventions for ventricular tachycardia.

Device Story

The ViaOne Epicardial Access System is a sterile, single-use tool designed for subxiphoid access to the pericardial space. It features a radiopaque distal tip that engages and retracts pericardial tissue away from the heart muscle, allowing a concealed needle to puncture the pericardium safely. A guidewire is then introduced through the needle, followed by an introducer and sheath to facilitate access to the epicardial surface. Used in an operating room setting under fluoroscopic guidance, the device is operated by clinicians to enable diagnostic and therapeutic interventions for ventricular tachycardia. By providing a controlled method for pericardial access, the device assists physicians in reaching the heart's surface, potentially improving procedural safety and success rates for cardiac electrophysiology interventions.

Clinical Evidence

Clinical evidence included a multi-center clinical trial involving patients with ventricular tachycardia. The primary endpoint assessed the occurrence and resolution of adverse events; secondary endpoints evaluated the success rate of pericardial space access. Results showed that adverse events were consistent with expected outcomes for similar epicardial procedures and were resolved without additional intervention. The study demonstrated a safety profile consistent with established standards.

Technological Characteristics

Sterile, single-use, 11 Fr device profile. Features a radiopaque distal tip and a mechanical engagement element for tissue retraction. Employs a 17.5 Ga. needle. Sterilized via Ethylene Oxide (EtO). Complies with ISO 10993-1 (biocompatibility), ISO 11135-1 (sterilization), and ISO 11070:2014 (introducer standards).

Indications for Use

Indicated for patients requiring epicardial access to the heart via a subxiphoid approach for diagnostic and therapeutic interventions related to ventricular tachycardia.

Regulatory Classification

Identification

A catheter introducer is a sheath used to facilitate placing a catheter through the skin into a vein or artery.

Predicate Devices

• EPi-Ease™ Epicardial Access System (EAS) (K233959)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue. Underneath the FDA logo is the word "ADMINISTRATION" in blue.

March 20, 2025

CardioVia Ltd. Orly Maor Company Regulatory Consultant Wadi El Haj, 13, P.O. Box 1252 Nazareth, 17111 Israel

Re: K243928

Trade/Device Name: ViaOne Epicardial Access System Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter introducer Regulatory Class: Class II Product Code: DYB Dated: December 16, 2024 Received: December 20, 2024

Dear Orly Maor:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory

{2}------------------------------------------------

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

# Aneesh S. Deoras -S

Aneesh Deoras Assistant Director Division of Cardiac Electrophysiology, Diagnostics, and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K243928

Device Name ViaOne Epicardial Access System

Indications for Use (Describe)

The ViaOne Epicardial Access System is intended to access the epicardial surface of the heart via a subxiphoid approach to deliver diagnostic and therapeutic interventions for ventricular tachycardia.

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|

|× | Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

# 510(k) Summary

# Traditional Premarket Notification Submission - 510(k) ViaOne Epicardial Access System 510(k) Number K243928

## Date Prepared: March 20, 2025

#### L SUBMITTER

CardioVia Ltd. Wadi El Haj, 13, P.O. Box 1252 1711 Nazareth, Israel M: +(972) 524807162 T: +(972) 46098609 W: www.cardiovia.com

# Contact Person

Orly Maor 25 Sirkin Street Kfar Saba 44421 Israel Tel: [phone] [e-mail]

#### II. DEVICE

Name of Device: ViaOne Epicardial Access System Common or Usual Name: ViaOne Classification Name: Introducer, Catheter Regulatory Class: Class II, per 21 CFR 870.1340 Product Code: DYB. Classification Panel: Cardiovascular

# III. PREDICATE DEVICE

CardioVia Ltd. believes that the ViaOne Epicardial Access System, which is the subject of this premarket notification, is substantially equivalent to the following predicate device:

- AtriCure, Inc. EPi-Ease™ Epicardial Access System (EAS) cleared under K233959 (product . code DYB Regulation No. 21 CFR 870.1340).
#### DEVICE DESCRIPTION IV.

ViaOne Epicardial Access System is a sterile, single-use access tool consisting of a concealed needle within a leading channel to facilitate guidewire access into the pericardium through a subxiphoid incision. The device consists of a radiopaque distal tip designed to retract a portion of the pericardial tissue into the device, and away from the heart muscle, where it is punctured by the concealed needle and a guidewire is introduced into the pericardial space.

{5}------------------------------------------------

#### INDICATIONS FOR USE v.

The ViaOne Epicardial Access System is intended to access the epicardial surface of the heart via a subxiphoid approach to deliver diagnostic and therapeutic interventions for ventricular tachycardia.

#### TECHNOLOGICAL CHARACTERISTICS WITH THE VI. COMPARISON OF PREDICATE DEVICE

ViaOne Epicardial Access System has the same intended use as the predicate device. Its indications for use are identical to that of the predicate device. The ViaOne Epicardial Access System has similar technological characteristics to the predicate device as demonstrated in the table below.

| Feature | Proposed:<br>ViaOne Epicardial<br>Access System | Predicate:<br>EPi-Ease™<br>Epicardial Access<br>System (EAS) | SE Justification |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 510(k) Number | K243928 | K233959 | |
| Manufacturer | CardioVia Ltd. | AtriCure, Inc. | |
| Product Code | DYB | DYB | Same |
| CFR | 21 CFR 870.1340 | 21 CFR 870.1340 | Same |
| Intended Use | The ViaOne<br>Epicardial Access<br>System is intended to<br>access the epicardial<br>surface of the heart via<br>a subxiphoid approach<br>to deliver diagnostic<br>and therapeutic<br>interventions for<br>ventricular<br>tachycardia. | The EPi-Ease™<br>Epicardial Access<br>System is intended<br>to access the<br>epicardial surface<br>of the heart via<br>subxiphoid<br>approach. | Same<br>Within the predicate<br>scope (The indication<br>was confirmed under<br>FDA's Breakthrough<br>Device Designation) |
| Access | Sub-xiphoid | Sub-xiphoid | Same |
| Needle size and<br>Device profile | 17.5 Ga. Needle<br>(similar to Tuohy - 17<br>Ga.)<br>11 Fr. device profile | 22 Ga. Tuohy<br>needle<br>18 Fr. device profile | Similar<br>ViaOne device profile<br>is 2/3 of the predicate<br>and the smaller needle<br>diameter has no impact<br>on safety as it is<br>concealed and intended<br>to puncture the<br>pericardium within the<br>tube |
| Visualization | Fluoroscopy required.<br>Endoscopic<br>visualization-Not<br>required | Fluoroscopy Required.<br>Endoscopic<br>visualization-Optional | Same |
| Feature | Proposed:<br>ViaOne Epicardial<br>Access System | Predicate:<br>EPi-Ease™<br>Epicardial Access<br>System (EAS) | SE Justification |
| Tissue retraction | Engagement<br>element enable<br>retraction | Vacuum enable<br>retraction | Different<br>Although capturing of<br>the tissue is performed<br>differently it brings the<br>same result of inserting<br>the pericardium into a<br>sealed compartment |
| Radiopaque marker | Yes-distal tip | Yes-distal tip | Same |
| Operating<br>Principles | Advancement<br>through adipose<br>tissue to reach<br>pericardial sac,<br>needle punctures<br>pericardial sac,<br>guidewire advances<br>through needle into<br>pericardial sac,<br>introducer advances<br>over guidewire and<br>pre- dilates<br>pericardial sac,<br>sheath advances<br>over guidewire into<br>pericardial sac to<br>access epicardial<br>surface of the heart.<br>Needle<br>advancement limits<br>to mitigate risks<br>associated with the<br>predicate. | Advancement<br>through adipose<br>tissue to reach<br>pericardial sac,<br>needle punctures<br>pericardial sac,<br>guidewire advances<br>through needle into<br>pericardial sac,<br>introducer advances<br>over guidewire and<br>pre- dilates<br>pericardial sac,<br>sheath advances<br>over guidewire into<br>pericardial sac to<br>access epicardial<br>surface of the heart.<br>Needle<br>advancement limits<br>to mitigate risks<br>associated with the<br>predicate. | Same |
| Reuse | Single Use. | Single Use. | Same |
| Environments of<br>Use | OR with imaging<br>equipment,<br>including<br>fluoroscopy under<br>sterile technique. | OR with imaging<br>equipment,<br>including<br>fluoroscopy under<br>sterile technique. | Same |
| Sterilization | Sterile for single<br>use (EtO). | Sterile for single<br>use (EtO). | Same |

{6}------------------------------------------------

{7}------------------------------------------------

# VII. PERFORMANCE DATA

The following performance data were conducted. The ViaOne Epicardial Access System met the predetermined acceptance criteria ensuring substantial equivalence to the predicate. No new safety or effectiveness issues were raised during testing:

#### . Biocompatibility

Biocompatibility evaluation in compliance with ISO 10993-1 was performed. The following tests were conducted:

- Cytotoxicity Study - ViaOne
- Cytotoxicity Study fluid path ●
- ISO Intracutaneous /irritation Study ●
- Sensitization Test ●
- . Acute Systemic Toxicity Study
- . Pyrogen Study - Material Mediated Study

All tests were successfully completed and passed, and the device met the defined acceptance criteria and was found to be biocompatible.

#### ● Sterilization, Packaging and Shelf Life Testing

Sterilization validation was performed to demonstrate compliance with ISO 11135-1. In addition, transportation simulation and environmental tests prior to real-time shelf life that included packaging testing and performance to support the one year labeled shelf life.

All tests were successfully completed and passed. and the device met the defined acceptance criteria.

#### ● Performance Testing

Performance testing included the following:

- Simulated Use O
- o Dimensions
- Visual inspection surface analysis O
- Spring force O
- Tensile Strength O
- Radiopacity o
- o Corrosion
- Engagement element functionality о
- · Verification testing, following ISO 11070:2014 standards including:
- Outer tube surface analysis
- Outer tube rim analysis
- Laser-cut flower shaft & outer tube rim inspection

All tests were successfully completed and passed, and the device met the defined acceptance criteria.

{8}------------------------------------------------

#### ● Animal Study

Animal Study evaluated the ViaOne Epicardial Access System safety and performance. The devices performed as intended without malfunction. The Histopathology evaluation and pathological examination indicated that there were or clinically significant events following use of the ViaOne Epicardial Access System.

#### ● Clinical Information

CardioVia provided information on clinical experience from its multi-central clinical trial which included VT subjects. The primary endpoint of the clinical study focused on the occurrence and resolution of adverse events associated with the ViaOne device. The secondary endpoint of the clinical study evaluated the success rate of pericardial space access. The observed adverse events were consistent with those expected in similar epicardial procedures and were resolved without additional intervention. The collected clinical data demonstrated a safety profile consistent with established standards and demonstrates that the ViaOne Epicardial Access System supports its intended use in the indicated population.

# VIII. CONCLUSIONS

CardioVia has demonstrated that the ViaOne Epicardial Access System is substantially equivalent in fundamental design, technology, function, device materials, packaging, sterilization, operating principal, and intended use/ indication for use to the predicate device, the EPi-Ease Epicardial Access System.